In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
News|Podcasts|February 24, 2026
ACT Brief: Site Data Quality Takes Priority, Merck Expands AI Discovery Efforts, and Gilead Advances Cell Therapy Strategy
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo Clinic are scaling AI-driven discovery, and how Gilead’s latest acquisition strengthens its position in cell therapy for multiple myeloma.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In Part 1 of a new video
interview series, Jonathan Andrus, co-CEO of CRIO, pointed to a growing shift toward site-based technologies as a defining operational trend for 2026. The focus is increasingly on capturing high-quality, compliant data at the point of care, as sponsors look to reduce downstream risk and enable more advanced analytics across the trial lifecycle. - Merck and Mayo Clinic have launched a new
collaboration aimed at applying AI and advanced analytics to drug discovery and precision medicine. By combining Merck’s research capabilities with Mayo Clinic’s multimodal data platform, the partnership is designed to improve target identification and support earlier, more informed decision-making across development. - Gilead Sciences is deepening its push into oncology with a $7.8 billion
acquisition of Arcellx, centered on an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. The therapy has demonstrated durable responses in clinical studies to date and is currently under FDA review, with a decision expected in late 2026 as the company looks to expand treatment options for heavily pretreated patients.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What ClinOps Professionals Just Starting With AI Should Keep Top of Mind
5